Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALCRL | Q16602 | 15/20 | 0.61 |
| ▸ | CALCA | P06881 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12050417 | 0.93 | CALCRL (0.57) | CALCRLCALCAALDH1A1HSD17B10KDM4E | |
| SCHEMBL12050423 | 0.81 | CALCRL (0.64) | CALCRLCALCA | |
| SCHEMBL12060842 | 0.80 | CALCRL (0.55) | CALCRLCALCAKDM4E | |
| SCHEMBL12050412 | 0.80 | CALCRL (0.69) | CALCRLCALCA | |
| SCHEMBL12050420 | 0.80 | CALCRL (0.64) | CALCRLCALCA | |
| SCHEMBL12050418 | 0.80 | CALCRL (0.57) | CALCRLCALCAALDH1A1 | |
| SCHEMBL12050163 | 0.79 | CALCRL (0.54) | CALCRLCALCA | |
| SCHEMBL12050619 | 0.79 | CALCRL (0.54) | CALCRLCALCAALDH1A1 | |
| SCHEMBL12050171 | 0.78 | CALCRL (0.53) | CALCRLCALCA | |
| SCHEMBL12061379 | 0.78 | CALCRL (0.53) | CALCRLCALCA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1951228-B1 | BICYCLIC SPIROHYDANTOIN CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2012-10-10 | — | — | EP | disclosed |
| US-8071771-B2 | Bicyclic spirohydantoin CGRP receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2011-12-06 | — | — | US | disclosed |
| US-8071771-B2 | Bicyclic spirohydantoin CGRP receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2011-12-06 | — | — | US | disclosed |
| US-20090176757-A1 | Bicyclic Spirohydantoin CGRP Receptor Antagonists | MERCK SHARP & DOHME LLC | 2009-07-09 | — | — | US | disclosed |
| US-20090176757-A1 | Bicyclic Spirohydantoin CGRP Receptor Antagonists | MERCK SHARP & DOHME LLC | 2009-07-09 | — | — | US | disclosed |
| WO-2007061695-A2 | BICYCLIC SPIROHYDANTOIN CGRP RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2007-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176757-A1 | Bicyclic Spirohydantoin CGRP Receptor Antagonists | BDKRB1, BDKRB2, CALCRL | CALCRL 3/4885CALCA 6/4885ALDH1A1 647/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.